HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) gapped down before the market opened on Tuesday . The stock had previously closed at $10.49, but opened at $9.84. HUTCHMED shares last traded at $9.93, with a volume of 1,963 shares.
Analyst Ratings Changes
Several equities analysts have weighed in on the stock. StockNews.com assumed coverage on shares of HUTCHMED in a research report on Wednesday, October 12th. They set a “hold” rating on the stock. The Goldman Sachs Group lifted their price objective on shares of HUTCHMED from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 9th.
HUTCHMED Stock Performance
The business’s 50 day simple moving average is $9.34 and its 200-day simple moving average is $11.09.
Institutional Investors Weigh In On HUTCHMED
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
- Get a free copy of the StockNews.com research report on HUTCHMED (HCM)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.